GSK to buy US biotech firm IDRx for up to $1.15 billion
British drugmaker GSK said today that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour.
Business
• 13 Jan
